# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0000950170-23-071499
Filing Date
2023-12-19
Accepted
2023-12-19 16:20:02
Documents
3

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFA14A | abio-defa14a_2023_noxbrl.htm | DEFA14A | 18661
2 | GRAPHIC | img168005826_0.jpg | GRAPHIC | 1259112
3 | GRAPHIC | img168005826_1.jpg | GRAPHIC | 263426
| Complete submission text file | 0000950170-23-071499.txt |  | 2116913

Mailing Address 10170 CHURCH RANCH WAY SUITE 100 WESTMINSTER CO 80021
Business Address 10170 CHURCH RANCH WAY SUITE 100 WESTMINSTER CO 80021 7209402200
ARCA biopharma, Inc. (Filer) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 000-22873 | Film No.: 231497543
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)